Antibodies engineered for intracellular function must not only have affinity for their target antigen, but must also be soluble and correctly folded in the cytoplasm. Commonly used methods for the display and screening of recombinant antibody libraries do not incorporate intracellular protein folding quality control, and, thus, the antigen-binding capability and cytoplasmic folding and solubility of antibodies engineered using these methods often must be engineered separately. Here, we describe a protocol to screen a recombinant library of single-chain variable fragment (scFv) antibodies for antigen-binding and proper cytoplasmic folding simultaneously. The method harnesses the intrinsic intracellular folding quality control mechanism of the Escherichia coli twin-arginine translocation (Tat) pathway to display an scFv library on the E. coli inner membrane. The Tat pathway ensures that only soluble, well-folded proteins are transported out of the cytoplasm and displayed on the inner membrane, thereby eliminating poorly folded scFvs prior to interrogation for antigen-binding. Following removal of the outer membrane, the scFvs displayed on the inner membrane are panned against a target antigen immobilized on magnetic beads to isolate scFvs that bind to the target antigen. An enzyme-linked immunosorbent assay (ELISA)-based secondary screen is used to identify the most promising scFvs for additional characterization. Antigen-binding and cytoplasmic solubility can be improved with subsequent rounds of mutagenesis and screening to engineer antibodies with high affinity and high cytoplasmic solubility for intracellular applications.
Introduction
Antibodies capable of folding and functioning in the intracellular environment are promising tools for both research and therapeutic applications. They have the ability to modulate protein activity by binding to a target protein inside cells to prevent protein-protein interactions, disrupt proteinnucleic acid interactions, or prevent substrate access to enzymes [1] [2] [3] [4] [5] .
Although antibodies have much potential for intracellular applications, engineering them for proper folding and solubility in the intracellular environment while maintaining the ability to bind to a target antigen is challenging. The reducing cytoplasmic environment prevents the formation of the disulfide bonds normally required for the stable folding of full-length antibodies and antibody fragments, including single-chain variable fragment (scFv) antibodies 6, 7 . A number of directed evolution approaches have been employed to engineer antibodies with high affinities for target antigens [8] [9] [10] . These approaches commonly use phage display, yeast surface display, or bacterial surface display to screen large libraries of antibodies [11] [12] [13] . These methods are powerful and effective for identifying antibodies that bind to targets, yet they depend on the secretory pathway to transport proteins that will be displayed [14] [15] [16] . The secretory pathway translocates unfolded proteins from the reducing cytoplasm into the endoplasmic reticulum lumen in yeast or into the periplasm in bacteria. The proteins then fold under oxidizing conditions and are displayed on the cell surface or packaged into phage particles to screen for binding affinity 17, 18 . As a result, antibodies isolated using these techniques will not necessarily fold well in the cytoplasm, and intracellular solubility must often be engineered separately if the antibodies will be used in intracellular applications.
To improve the efficiency of engineering antibodies that are well folded in the cytoplasm, we previously reported the success of MAD-TRAP (membrane-anchored display for Tat-based recognition of associating proteins), a method for screening an scFv antibody library using Escherichia coli inner-membrane display 19 . Bacterial inner-membrane display relies on the twin-arginine translocation (Tat) pathway for transporting displayed antibodies, in contrast to other common display methods that use the secretory pathway. The Tat pathway contains a quality control mechanism that only allows soluble, correctly folded proteins to be transported from the E. coli cytoplasm, across the inner membrane, and into the periplasm 20, 21 . Overexpressed Tat substrates (i.e., proteins targeted to the Tat pathway with an N-terminal fusion to the Tat signal peptide ssTorA) that are well folded in the cytoplasm form a long-lived translocation intermediate with the N-terminus in the cytoplasm and the C-terminus in the periplasm Figure 1 . Tat inner-membrane display. In E. coli, scFv antibodies that are expressed as a fusion to the ssTorA signal sequence and correctly folded in the cytoplasm are transported across the inner membrane. A translocation intermediate forms, where the scFvs are anchored in the inner membrane with the N-terminus in the cytoplasm and the C-terminus in the periplasm. The E. coli outer membrane is enzymatically digested to form spheroplasts, thereby exposing the anchored antibodies to the extracellular space and making them available for detection by using an antibody that binds to the C-terminally fused epitope tag on the displayed antibody. Please click here to view a larger version of this figure. NOTE: The library may also be constructed using any appropriate mode to generate diversity over the entire scFv gene or targeted domains (e.g., the third complementarity determining regions, CDR3s) 22 . 2. Insert the DNA library into the pIMD plasmid (Figure 2 ) using standard molecular cloning methods . This plasmid contains a lac promotor, ColE1 origin of replication, and a chloramphenicol resistance gene. The inserted scFv gene is fused to the ssTorA signal sequence to target the scFv to the Tat pathway and to a FLAG epitope tag, with all three in the same reading frame. Restriction enzyme sites are indicated. For a library inserted between the XbaI and NotI restriction enzyme sites, the size of the plasmid is 2219 bp plus the size of the scFv. Please click here to view a larger version of this figure.
3. Transform the plasmid DNA containing the library into MC4100 E. coli cells 23 . Recover and grow this bacterial form of the library. Centrifuge at 4,000× g for 15 min at RT to collect the cells. Remove the supernatant, and resuspend the collected cells in 25% glycerol in Luria-Bertani (LB) media. Store aliquots at -80 °C until needed, or proceed to Step 2. NOTE: The protocol has been verified with MC4100 cells, though other E. coli strains are also expected to be compatible with the protocol. Electroporation is the preferred method for transformation, due to its high transformation efficiency. The library should typically consist of at least 10 9 scFv variants at this stage, and each aliquot should contain enough cells such that the library is covered 100-fold.
Express the Library and Prepare Spheroplasts
1. Thaw one aliquot of the bacterial library (from Step 1.3) at RT, and add the aliquot to a flask containing 100 ml LB media with 20 µg/ml chloramphenicol (Cm). Grow for 3 hr at 37 °C and 225 rpm in an incubated shaker. After spheroplasting using EDTA and lysozyme, the outer membrane of the E. coli cells is ruptured, and the resulting spheroplasts are spherical in shape. Differential interference contrast (DIC) microscopy images were obtained using a 100X objective on an inverted microscope. Please click here to view a larger version of this figure.
3. Prepare the library spheroplasts. NOTE: Spheroplasts are formed by rupturing the outer membrane of E. coli and are spherical in shape (Figure 3 
3.
Centrifuge the calculated volume of induced culture in a 1.5 ml microcentrifuge tube at 12,000 × g at RT for 5 min. Prepare at least two samples in the event that an issue arises in sample preparation. 4. Remove the supernatant from the centrifuged cultures and resuspend each cell pellet in 100 µl of ice-cold FB. Centrifuge at 12,000 × g at RT for 1 min, and then remove the supernatant by pipetting. Resuspend each pellet in 350 µl of ice-cold FB supplemented with 3.5 µl of 10 mg/ml lysozyme. 5. Slowly vortex each tube while adding, dropwise, 700 µl of 1 mM EDTA, and then incubate the tubes at RT for 20 min while slowly rotating on a tube rotator to mix the samples. Remove the tubes from the rotator, add 50 µl of ice-cold 0.5 M MgCl 2 to each tube, and incubate them on ice for 10 min. Centrifuge the tubes at 11,000 × g at 4 °C for 10 min. 6. Isolate the spheroplast pellet.
1. Use a micropipette with a 1 ml tip to slowly pull up part of pellet. While holding the tube at an angle with the opening directly above a new 1.5 ml tube, slowly lift the pipette tip out of the supernatant and slide the pellet into the new tube. 2. If a significant volume of supernatant is transferred to the new tube, remove it by pipetting. If the pellet is not firm enough to transfer, re-centrifuge at 11,000 × g for 2 min and attempt pellet isolation again.
7. Resuspend the spheroplast pellet in each tube in 1 ml of ice-cold 1× PBS. Alternate between pipetting and slowly vortexing on a vortex holder until the pellet is fully resuspended. Do not keep samples off of the ice for more than 2 min at a time, and return to the ice for at least 5 min before removing from the ice again. Keep the spheroplasts at 4 °C (for up to 2 days) until used for panning in Step 4.
Immobilize the Target Antigen onto Magnetic Beads
1. Biotinylate the target antigen in vivo during recombinant production in E. coli cells. Alternatively, use chemical conjugation 25 or purchase target antigen that has already been biotinylated, and proceed to Step 3.2.
1. Add 816 g bicine to 50 ml water to make 10× bicine buffer. Dilute the buffer to 1× in distilled H 2 O and heat to 50 °C. Add 14.7 mg biotin to 12 ml of the heated 1× bicine buffer to make a biotin solution that is 5 mM biotin in 10 mM bicine buffer. Store at -20 °C until needed. 2. Express and biotinylate the target protein using the pAK400cb-BCCP plasmid 26 , which allows production of the target antigen as a fusion to the biotin carboxyl carrier protein (BCCP). NOTE: E. coli cells natively biotinylate BCCP, eliminating the need to purify and chemically biotinylate the target protein prior to immobilization on streptavidin-coated beads. The native E. coli biotin ligase BirA is sufficient for biotinylating the fusion protein.
1. Grow E. coli containing the biotinylation plasmid (with the target antigen inserted as a fusion to the N-terminus of BCCP) O/N for 15 to 18 hr in 5 ml of LB media supplemented with 20 µg/ml Cm at 37 °C while shaking at 225 rpm. 4. Re-circularize the whole-plasmid PCR products, and use the ligated product to transform MC4100 E. coli cells. 1. Purify the PCR product by running the PCR reaction on an agarose gel 23 , staining the DNA in the gel 23 , and using a gel cleanup kit to purify the linearized plasmid by following the instructions supplied by the manufacturer. Measure the concentration using a spectrophotometer at 260 nm. Store the purified fragment at -20 °C until needed, or continue to Step 4.4.2. 2. Re-circularize plasmid from the PCR product.
1. To prevent intermolecular ligation of the PCR product, carry out the ligation reaction with a low concentration 27 of 1 ng/µl of PCR product. Calculate the volume needed for preparing an 800 µl ligation reaction at this concentration. 1. Dilute purified target antigen to an appropriate concentration (e.g., 1 µg/ml to 4 µg/ml) in 1× PBS to make the coating solution. Make 5 ml of coating solution for each 96-well plate. NOTE: The appropriate concentration depends on the specific antigen being used and may need to be adjusted. Inner-membrane display can successfully isolate scFv antibodies with high levels of affinity for a target protein and high levels of cytoplasmic solubility. Additionally, subsequent rounds of directed evolution using inner-membrane display improve antibody characteristics 19 . To demonstrate this, an error-prone PCR library based on scFv13, which has a low level of binding affinity for β-galactosidase, was panned against the target antigen β-galactosidase using the display and panning method described in the protocol. scFv 1-4 was isolated after one round of mutagenesis and panning, and exhibited higher binding affinity to β-galactosidase than scFv13 ( Figure 7A ) and a higher level of cytoplasmic solubility ( Figure  7B ).
Perform a Secondary Screen Using an Enzyme-linked Immunosorbent Assay Method to
A new library, based on scFv 1-4, was made using error-prone PCR, and panning of this second-generation library against β-galactosidase was done using a modification of the described protocol. The panning against β-galactosidase for the second round of evolution was done in the presence of purified, soluble scFv 14 as a competitor to improve the likelihood of isolating clones with higher affinity than scFv 1-4. After this second round of mutagenesis and panning, scFv 2-1 and scFv 2-3 were isolated using the ELISA-based secondary screening. These scFvs not only exhibited higher binding affinity for β-galactosidase than scFv13, but also exhibited better binding than the first-round clone scFv 1-4. scFv 2-1 exhibited β-galactosidase binding comparable to that of scFv13.R4 ( Figure 7A) . scFv 2-3 also shows a further increase in cytoplasmic solubility compared to scFv 14, highlighting the simultaneous engineering of solubility and antigen-binding. Since affinity and soluble expression of the scFvs are screened for simultaneously, it is possible that a selected scFv has moderate solubility but high binding or vice versa. For example, scFv 2-1 has lower soluble expression than scFv 2-3, but it exhibits higher binding affinity to β-galactosidase. 
Discussion
Engineering antibodies for cytoplasmic activity is a difficult task due to the reducing milieu of the cytoplasm, which impedes the formation of stabilizing disulfide bonds 6, 7 . This causes most antibodies to be cytoplasmically inactive unless they are engineered for stability and solubility in the cytoplasm, in addition to being engineered for binding affinity. The existing methods of phage display, bacterial surface display, and yeast surface display methods all use the secretory pathway [14] [15] [16] for the display of engineered antibodies, but these methods have no means to engineer intracellular folding. Antibodies engineered using inner-membrane display have improved cytoplasmic stability and solubility because the folding quality control of the Tat pathway prevents translocation of antibodies that are poorly folded and unstable in the cytoplasm. This method simplifies the iterative process of engineering intracellular antibodies for affinity and solubility, as the two properties are engineered in one step. Although this method was designed for engineering antibodies with solubility in the reducing intracellular environment, it could also be applied to engineering antibodies to function in non-reducing conditions, since the proteins engineered using this method maintain their folding in the oxidizing environment of the periplasm.
Although this technique simplifies the process of engineering antibodies with high affinity and high cytoplasmic solubility, several limitations are important to consider when using this protocol. When analyzing the secondary screen ELISA signals to identify promising scFv variants, the threshold for discerning between potentially interesting variants and those that may not exhibit adequate antigen-binding is not likely to be apparent until after several clones have been further characterized. It is important to look for improved binding over the parent antibody; however, an abnormally high signal could be indicative of avidity 29 or aggregation effects 30 , a challenge which is not unique to the innermembrane display screening approach. A key limitation to remember when using this protocol is the inability to recover spheroplasts after panning, as they are non-viable (unpublished data). This necessitates the DNA amplification and transformation steps to recover the antibodyencoding plasmids.
Several critical steps of the protocol enable the simultaneous engineering of folding and binding of antibodies. For screening to be successful, the scFv library being screened must be expressed as a fusion to the ssTorA signal peptide. Without this sequence, antibodies will not be directed to the Tat pathway and thus will not be translocated to the periplasm 19 . Additionally, it is imperative that a C-terminal epitope tag is fused to the antibodies to allow detection of the displayed antibodies in the binding assays. Clearly, the E. coli strain used to express the scFvs must also have the necessary Tat pathway machinery, but this is true of the commonly used E. coli strains.
Modifications to this protocol are possible to improve its potential to isolate antibodies with the desired characteristics. A subtractive panning step may be completed prior to panning against the target antigen to deplete the scFv library of non-desired constituents. The library spheroplasts can be incubated with magnetic beads coated with BCCP alone or coated with a non-desired protein, and the spheroplasts that bind to those beads can be discarded before screening the remaining unbound spheroplasts for binding to the desired target. As mentioned in the Representative Results, a method to improve the affinity of an isolated scFv is to include a soluble competitor in the panning reaction to compete with the scFvs displayed on the spheroplasts. Because the soluble competitor is a purified protein, no DNA is amplified from it, so only sequences of the scFvs displayed on the spheroplasts will be recovered in the PCR reaction. Additionally, this method could be extended to engineering other types of antibodies or to non-antibody binding proteins.
E. coli inner-membrane display is a powerful platform for engineering antibodies with high affinity and high levels of intracellular solubility. This method is particularly suited for efficient engineering of antibodies designed to function in the intracellular environment. These intracellular antibodies are already being explored as potential therapeutics in a number of fields, including neurodegenerative diseases, cancer, and viral infections 31 . This technique will enable more widespread use of intracellular antibodies as tools for research and medicine in these fields and any other field where studying a protein target in situ is desired.
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